5. Patient characteristics of the agreement analyses studies.
| Study | Population | Median age (range) | Median PSA in ng/mL (range) | Median prostate volume in cm3 (range) |
| Alberts 2017a | Bx‐naïve Prior‐negative Bx | 73 (72‐74b) | 4.2 (3.4–5.8b) | 53 (37‐71b) |
| Boesen 2017a | Prior‐negative Bx | 65 (58‐68b) | 12.8 (8.9‐19.6b) | NR |
| Boesen 2018 | Bx‐naïve | 67 (61‐71b) | 8 (5.7‐13b) | 53 (40‐72b) |
| Castellucci 2017 | Bx‐naïve | 61 (8)c | 8.3 (6.1)c | 49 (7)c |
| Chang 2017 | Prior‐negative Bx | 64 (60‐68b) | 10.9 (7.2‐14.7b) | 48 (34‐63b) |
| Chen 2015 | Bx‐naïve | 67 (45‐91) | 9.7 (2.4‐35.7) | 45 (21‐83) |
| Cool 2016 | Bx‐naïve Prior‐negative Bx | 59 (8)c 62 (7)c | 6.0 (3.5)c 7.9 (3.9)c | 38 (18)c 56 (27)c |
| Costa 2013 | Prior‐negative Bx | 64 (48‐77)c | 14.4 (1.8‐33.1)c | NR |
| Delongchamps 2013 | Bx‐naïve | 64 (7)c | 8.5 (3.9)c | 56 (30)c |
| Filson 2016 | Bx‐naïve Prior‐negative Bx | 64 (59‐69b) 66 (59‐70b) | 5.8 (4.4‐8.1b) 7.6 (5‐11.5b) | 45(33‐62b) 58 (40‐84b) |
| Garcia Bennett 2017 | Bx‐naïve | 64 (6.7)c | 7.2 (6‐9.4b) | 48 (35‐63b) |
| Grönberg 2018a | Bx‐naïve Prior‐negative Bx | 64 (45–74)c | 6.3 (4.4b) | (32‐70)d |
| Jambor 2015 | Bx‐naïve | 66 (47‐76) | 7.4 (4‐14) | 42 (17‐107) |
| Jambor 2017a | Mixed | 65 (6)c | 7.5 (5.7‐9.6b) | 37 (28‐49b) |
| Kim 2017 | Bx‐naïve Prior‐negative Bx | 64 (7)c | 10.2 (15.1)c | NR |
| Lee 2016 | Bx‐naïve | 66 (43‐83) | 6.4 (3.3‐9.8) | 39 (17‐127) |
| Lee 2017 | Bx‐naïve | 62 (10)c | 6.4 (1.8)c | 40 (18)c |
| Okcelik 2016 | Bx‐naïve | 62 (43‐79) | 5 (3‐8.9) | 45 (17‐93) |
| Panebianco 2015a | Bx‐naïve Prior‐negative Bx | 64 (51‐82) | NR | NR |
| Peltier 2015 | Bx‐naïve | 65 (7)c | 8.4 (6.3)c | 49 (22)c |
| Pokorny 2014 | Bx‐naïve | 63 (57‐68b) | 5.3 (4.1‐6.6b) | 41 (30‐59b) |
| Rouvière 2019a | Bx‐naïve | 64 (59‐68b) | 6.5 (5.6‐9.6b) | 50 (38‐63b) |
| Say 2016 | Prior‐negative Bx | 64 (47‐82)c | 11.59 (0.4‐96.9)c | 69 (17‐309)c |
| Tonttilla 2016 | Bx‐naïve | 63 (60‐66b) | 6.1 (4.2‐9.9b) | 28 (24‐37b) |
| Van der Leest 2018 | Bx‐naïve | 65 (59‐68b) | 6.4 (4.6‐8.2b) | 55 (41‐77b) |
| Bx: biopsy; NR: not reported; PSA: prostate specific antigen | ||||
aResults not reported per population type. bInterquartile range (as apposed to range). cMean (SD or range) (as opposed to median (range)). dRange of interquartile ranges across three centres.